Feature | CT Angiography (CTA) | October 18, 2015

FFR-CT Shown to Reduce Costs in Patients with Chest Pain

Cost and quality of life outcomes from the PLATFORM Trial reported at TCT 2015

FFR-CT, cost and quality of life outcomes, TCT 2015, PLATFORM trial

October 18, 2015 — New results from a multicenter, prospective study show that assessing fractional flow reserve estimated with computed tomography (FFR-CT) may reduce costs in selected symptomatic patients with suspected coronary artery disease (CAD).

Cost and quality of life outcomes from the PLATFORM trial were reported at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). The study was also published in the Journal of the American College of Cardiology.

Fractional flow reserve (FFR) measures blood pressure and flow through a specific part of the coronary artery. It has typically been assessed using invasive catheter-based tests but can now be measured non-invasively using FFR-CT. The clinical effectiveness of using FFR-CT to guide management, compared with conventional testing, was recently demonstrated in the PLATFORM (Prospective Longitudinal Trial of FFR-CT: Outcomes and Resource Impacts) study. FFR-CT was also recently approved for clinical use by the U.S. Food and Drug Administration and received a CE mark in Europe.

 The purpose of this study was to assess the economic and quality of life outcomes of evaluation strategies that use FFR-CT, based on data collected prospectively from the non-randomized PLATFORM study. Five hundred eighty-four symptomatic patients with suspected CAD were enrolled at 11 European centers (204 in the planned non-invasive testing stratum and 380 in the planned invasive testing stratum). Within the planned non-invasive testing stratum, 100 patients were evaluated with the usual care strategy, and 104 patients were evaluated with the FFR-CT strategy. In the planned invasive testing stratum, 187 patients were evaluated with the usual care strategy, and 193 patients were evaluated with the FFR-CT strategy.

The number of diagnostic tests, invasive procedures, hospitalizations and medications after 90 days were multiplied by U.S. cost weights and summed to derive total medical costs. Changes in quality of life (QOL) from baseline to 90 days were assessed using the Seattle Angina Questionnaire (SAQ), the EuroQOL (EQ-5D) and a visual analog scale (VAS).

In the 584 patients, 74 percent had atypical angina, and the pre-test probability of coronary disease was 49 percent. In the planned invasive stratum, mean costs were 32 percent lower among the FFR-CT patients than among the usual care patients who typically underwent invasive coronary angiography ($7,343 vs. $10,734, p<0.0001). In the non-invasive stratum, mean costs were not significantly different between the FFR-CT patients and the usual care patients who underwent traditional non-invasive risk stratification ($2,679 vs. $2,137, p=0.26).

In a sensitivity analysis, when the cost weight of FFR-CT was set to seven times that of CTA, the FFR-CT group still had lower costs than in the usual care group in the invasive testing stratum ($8,619 vs. $10,734, p < 0.0001) while in the noninvasive testing stratum, when the cost weight of FFR-CT was set to half that of CTA, the FFR-CT group had higher costs than the usual care group ($2,766 vs. $2,137, p=0.02).

Each quality of life (QOL) score improved in the overall study population (p<0.0001). In the noninvasive stratum, QOL scores improved more in FFR-CT patients than in usual care patients: SAQ 19.5 vs. 11.4, p=0.003; EQ-5D 0.08 vs. 0.03, p=0.002; and VAS 4.1 vs 2.3, p=0.82. In the invasive cohort, the improvements in QOL were similar in the FFR-CT and usual care patients.

“These results suggest that use of FFR-CT might reduce overall costs and improve patient quality of life,” said lead researcher Mark Andrew Hlatky, M.D. Hlatky is professor of health research and policy and of medicine at the Stanford University School of Medicine in California. “Larger, randomized studies are warranted to compare the clinical effectiveness of management strategies based on use of FFR-CT with management strategies based on using other methods of anatomic or functional evaluation.”

The study was funded by HeartFlow Inc. Hlatky reported research grants from HeartFlow.

Watch the VIDEO “Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation.” A discussion with Simon Dixon, M.D., MBChB, on the use of fractional flow reserve-computed tomography (FFR-CT) to evaluate chest pain patients in the emergency department. He is chairman of the Department of Cardiovascular Medicine at Beaumont Health System and a professor of Medicine at the Oakland University William Beaumont School of Medicine. He discussed the first year of experience with FFR-CT at Beaumont Hospital in Royal Oak, Mich., during the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting. 

For more information: www.tctconference.com

Related Content

Feature | Cardiovascular Business | By Dave Fornell, DAIC Editor

November 12, 2021 — President Joe Biden today announced his intention to nominate cardiologist Robert Califf, M.D., MACC ...

Home November 12, 2021
Home
News | Cardiovascular Business

November 10, 2021 — Shockwave Medical, a developer of Intravascular Lithotripsy (IVL) to treat complex calcified ...

Home November 10, 2021
Home
News | Cardiovascular Business

October 15, 2021 — The American Heart Association (AHA) released a new policy statement that offers policy ...

Home October 15, 2021
Home
Feature | Cardiovascular Business

June 10, 2021 — Diagnostic and Interventional Cardiology (DAIC) magazine has won a prestigious Jesse H. Neal Award for ...

Home June 10, 2021
Home
News | Cardiovascular Business

May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) ...

Home May 05, 2021
Home
News | Cardiovascular Business

March 12, 2021 — Cardinal Health today announced that it is selling its Cordis cardiology and endovascular business to ...

Home March 12, 2021
Home
News | Cardiovascular Business

February 3, 2021 — Modern Vascular is a medical group that has 13 outpatient cath lab clinics to treat peripheral artery ...

Home February 03, 2021
Home
Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 01, 2020
Home
News | Cardiovascular Business

September 14, 2020 — New global research released by Abbott takes a deep dive into the barriers of cardiovascular ...

Home September 14, 2020
Home
Videos | Cardiovascular Business

Nick West, M.D., chief medical officer for Abbott, explains the details from a survey of 1,400 patients, physicians and ...

Home September 14, 2020
Home
Subscribe Now